Kevin O’Connor and Mike Harlin, partners in the firm’s Intellectual Property practice, recently coauthored the article “The Expanding Patent Landscape for RNA-Based Therapeutics” published on BioProcess Online. In the article, Kevin and Mike explore renewed interest in and further development of RNA-based therapeutics following the success of the COVID-19 mRNA vaccines. They examine why RNA-based therapeutics are currently seeing more patent activity and address how developers of therapeutics can mitigate patent risks. 

Click here to read the article.